Research and Markets: Learn How Roche Is Forecast To Achieve The Strongest Ethical Sales Growth Rate Among The Big Pharma Peer Set Over 2005-11.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45431) has announced the addition of "Roche: PharmaVitae Profile 2005" to their offering.

This Company Analysis examines the historical and forecast performance for Roche in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast

A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.

Reasons to order your copy:

* Benchmark Roches performance against key rivals in the ethical pharmaceutical sector

* Learn how Roche is forecast to achieve the strongest ethical sales growth rate among the Big pharma peer set over 2005-11

* Understand how Roche is located in the high growth therapy areas of oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors.

on·col·o·gy
n. and AIID AIID Autoimmune and Inflammatory Disorders
AIID Association des Infirmiers(ères) Intervenant(e)s en Diabétologie , while much of Big Pharma remains entrenched en·trench also in·trench
v. en·trenched, en·trench·ing, en·trench·es

v.tr.
1. To provide with a trench, especially for the purpose of fortifying or defending.

2. in CV and CNS See Continuous net settlement.

CNS

See continuous net settlement (CNS).

Topics Covered:

* Executive summary

* Corporate history

* Historical performance

* Forecast performance

* Key products and competitors

For more information visit http://www.researchandmarkets.com/reports/c45431

Source: Datamonitor

COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Date:	Nov 16, 2006
Words:	163
Previous Article:	Israeli Court Approves SanDisk Acquisition of msystems.
Next Article:	The Book 'Global Engineering and Construction' Provides a Useful Glossary and Numerous Case Studies Illustrating Practices in the Real World.
Topics:	Pharmaceutical industry Ethical aspects Industry forecasts

Related Articles
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Research and Markets: Examine AstraZeneca's Performance Against Key Rivals in the Ethical Pharmaceutical Sector.
The Future of the Pharmaceutical Industry: Big Change Expected for Next Years.
Analyze Historical and Forecast Ethical Sales Performance of Pharmaceutical Group Altana.
From July 2005 - June 2006, the Total Sales of Pharma Products Went up by 14.5% to RON 4.9Bn (EUR 1.39Bn).
Research and Markets: Benchmark Boehringer Ingelheim's Performance against Key Rivals in the Ethical Pharmaceutical Sector in This 2006 Pharmavitae...
As Patent Expiries Take Their Toll On Small Molecule Blockbuster Drugs Big Pharma Are Turning To Biologic Therapies To Drive Future Growth.
Research and Markets : Analyze the Financial Performance of Schering AG in the Ethical Pharmaceutical Sector.
Biotech to See 10.1% Sales CAGR Between 2005 and 2011 According to New Report.
Research & Markets: Gilead Sciences Acquisitions of Myogen and Corus Pharma Has Significantly Expanded the Scope of Their Research Efforts.